Genomic and transcriptomic landscape of HER2-low breast cancer.
Publication Title
Breast cancer research and treatment
Document Type
Article
Publication Date
9-20-2024
Keywords
Breast cancer; Genomic profile; HER2 low; Hormone receptor positive; PIK3CA; TP53; Triple negative breast cancer.; california; sjci; genomics
Abstract
BACKGROUND: Novel agents have expanded the traditional HER2 definitions to include HER2-Low (HER2L) Breast Cancer (BC). We sought to evaluate the distinct molecular characteristics of HER2L BC to understand potential clinical/biologic factors driving resistance and clinical outcomes.
METHODS: Retrospective analysis was performed on 13,613 BC samples, tested at Caris Life Sciences via NextGen DNA/RNA Sequencing. BC subtypes were defined by IHC/ISH. CODEai database was used to access clinical outcomes from insurance claims data.
RESULTS: Overall, mutational landscape was similar between HER2L and classical subsets of HR+and HRneg cohorts. TP53 mutations were significantly higher in HRneg/HER2L group vs. HR+/HER2L tumors (p
CONCLUSION: Our findings expand the understanding of the molecular profile of the HER2L subgroup and comparison to the classically defined breast cancer subgroups. Genomic risk assessments after progression on novel therapeutics can be assessed to better define implications for mechanisms of resistance.
Clinical Institute
Cancer
Clinical Institute
Women & Children
Specialty/Research Institute
Oncology
DOI
10.1007/s10549-024-07495-4
